Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 220

Posts Tagged ‘complete’

Bain Capital complete acquisition of RBS WorldPay

Posted by fidest press agency su giovedì, 2 dicembre 2010

London – Bain Capital and Advent International, the leading global private equity firms, have today announced the completion of the purchase of global payments services provider RBS WorldPay from The Royal Bank of Scotland Group plc (RBSG). RBS will retain a minority stake in the company.   The new company, to be known as WorldPay, is the largest provider of card payment services in the UK and Europe and the fourth largest globally. In 2009, the business processed a total of 6.8bn transactions worldwide with a value of £243bn. Headquartered in the UK, WorldPay employs over 2,600 people in more than 30 markets throughout Europe, the US and Asia.  The market for electronic payments is growing significantly due to the continuing shift from paper-based payments, such as cash and cheques, to electronic payments like credit and debit cards, the most prevalent form of electronic payment.  Between 2008 and 2013, the total number of card payment transactions globally is forecast to grow at a CAGR of 10.5%.  New payment methods, increasingly online, are also being adopted, with the value of eCommerce transactions between 2009 and 2013 expected to grow at a CAGR of 18.8%.  Particular opportunities are anticipated in emerging markets, as their economies develop and expand.
Founded in 1984, Advent International is one of the world’s leading global buyout firms, with offices in 17 countries on four continents. A driving force in international private equity for 26 years, Advent has built an unparalleled global platform of over 160 investment professionals across Western and Central Europe, North America, Latin America and Asia. The firm focuses on international buyouts, strategic repositioning opportunities and growth buyouts in five core sectors, working actively with management teams to drive revenue growth and earnings improvements in portfolio companies. Since inception, Advent has raised €19.4bn ($25bn) in private equity capital and, through its buyout programs, has completed over 250 transactions valued at approximately €40bn ($52bn) in 35 countries.
Bain Capital is one of the world’s leading private investment firms with approximately $67bn in assets under management and a team of over 300 investment professionals located across 3 continents and 8 offices. Since its inception in 1984, Bain Capital has made private equity investments and add-on acquisitions in over 300 companies, focusing on market leading businesses and world class management teams. Bain Capital has a distinctly people-intensive, value-added approach to investing, with a strong emphasize on supporting management teams to drive strategic and operating improvements. The firm’s Managing Directors follow a long-standing tradition of operating as a consensus-oriented partnership, personally committing themselves at every stage of the investment process, and partnering with management to ensure the success of their portfolio companies.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

To treat chronic lymphocytic leukemia

Posted by fidest press agency su giovedì, 13 agosto 2009

Copenhagen, Denmark Genmab A/S (OMX: GEN) announced top-line results from the Phase II study of Arzerra(TM) (ofatumumab) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated patients. A total of 61 patients were treated in the study. Treatment response was assessed using the 1996 National Cancer Institute Guidelines. The complete remission rate was 32% in patients who received 500 mg of ofatumumab (n=31) and 50% in patients who received 1000 mg of ofatumumab (n=30). The overall response rate was 77% in the 500 mg treatment group and 73% in the 1000 mg treatment group.There were no unexpected safety findings reported during treatment and within 30 days after last infusion. The most common adverse event reported was neutropenia at 48%. Other common adverse events (greater that 15 percent) were nausea, leukopenia, rash, vomiting, pyrexia, headache and thrombocytopenia. The number of patients, who experienced adverse events, including serious adverse events, was similar between the two dose groups. One death was reported and was judged by the investigator as unrelated to ofatumumab. Patients in this open label study were randomized into two treatment groups. Each patient was to receive one infusion of 300 mg of ofatumumab in combination with FC followed by 5 monthly infusions of either 500 or 1000 mg of ofatumumab in combination with FC. Disease status was measured every 4 weeks until week 24 and every 3 months thereafter until disease progression or 24 months. Treatment response was assessed according to the 1996 National Cancer Institute Working Group guidelines by an Independent endpoints Review Committee. Patients nothaving progressed on their disease at 24 months will be followed for disease progression at 6 month intervals until 60 months.The objective of the study was to determine the efficacy of ofatumumab in combination with FC in previously untreated CLL patients. The primary endpoint was complete remission rate from start of treatment until 3 months aftelast infusion. Ofatumumab is a novel, investigational, fully human monoclonal antibody that targets a membrane-proximal (close to the cell surface) small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule of B-cells. This epitope is different from the binding sites targeted by other CD20 antibodies currently available.The CD20 molecule is a key target in CLLtherapy because it is expressed on most B-cells in CLL patients. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country Genma is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »